2007;2:1360–6 PubMedCrossRef 2 Nakai S, Wada A, Kitaoka T, Shinz

2007;2:1360–6.PubMedCrossRef 2. Nakai S, Wada A, Kitaoka T, Shinzato T, Nagura Y, Kikuchi K, et al. Cediranib An overview of regular dialysis treatment in Japan (as of 31 December 2004). Ther Apher Dial. 2006;10:476–97.PubMedCrossRef 3. Li PK, Weening JJ, Dirks J, Lui SL, Szeto CC, Tang S, et al. A report with consensus statements of the International Society of Nephrology 2004 Consensus Workshop on Prevention of Progression of Renal Disease, Hong Kong, June 29, 2004. Kidney Int Suppl 2005;94:S2–7. 4. Dirks JH, de Zeeuw D, Agarwal SK,

Atkins RC, Correa-Rotter R, D’Amico G, et al. Prevention of chronic kidney and vascular disease: toward global health equity—the Bellagio 2004 declaration. Kidney Int Suppl. 2005;98:S1–6.PubMedCrossRef 5. Eknoyan G, Lameire N, Barsoum R, Eckardt KU, Levin A, Levin N, et al. The burden of kidney disease: improving global outcomes. Kidney Int. 2004;66:1310–4.PubMedCrossRef 6. Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, et al. Chronic kidney disease as a global public health problem: approaches and initiatives—a position statement from Kidney Disease Ganetespib Improving Global Outcomes. Kidney Int. 2007;72:247–59.PubMedCrossRef 7. Levey AS, Eckardt KU, Tsukamoto

Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089–100.PubMedCrossRef 8. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2006;69:1945–53.PubMedCrossRef 9. Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of Hepatitis C in chronic kidney disease. Kidney Int 2008;73:S1–99. 10. Harris D, Thomas M, Johnson D, Nicholls K, Gillin A. The CARI guidelines. Prevention of progression of kidney disease. Carbohydrate Nephrology (Carlton). 2006;11(Suppl 1):S2–197.CrossRef 11. Dirks JH, Robinson SW. The

global perspective of the International Society of Nephrology: a decade of experience with COMGAN. Kidney Int. 2005;68:1395–410.PubMedCrossRef 12. Modi GK, Jha V. The incidence of end-stage renal disease in India: a population-based study. Kidney Int 2006;70:2131–3. 13. Nakai S, Masakane I, Akiba T, Iseki K, Watanabe Y, Itami N, et al. Overview of regular dialysis treatment in Japan (as of 31 December 2005). Ther Apher Dial. 2007;11:411–41.PubMedCrossRef 14. Iseki K, Tohyama K, Matsumoto T, Nakamura H. High Prevalence of chronic kidney disease among patients with sleep https://www.selleckchem.com/products/BafilomycinA1.html related breathing disorder (SRBD). Hypertens Res. 2008;31:249–55.PubMedCrossRef 15. White SL, Polkinghorne KR, Cass A, Shaw J, Atkins RC, Chadban SJ. Limited knowledge of kidney disease in a survey of AusDiab study participants. Med J Aust. 2008;188:204–8.PubMed 16.

Comments are closed.